Theravance announced a decisive strategic retrenchment after its norepinephrine reuptake inhibitor ampreloxetine failed a pivotal Phase 3 study in multiple system atrophy and related neurogenic orthostatic hypotension populations. The company said it will wind down its entire R&D organization and cut about half of its workforce, leaving commercialized respiratory assets as the primary near-term cash generators. The Phase 3 miss closes the book on ampreloxetine after prior late‑stage setbacks and forces management to prioritize financial stability and cash-flow generation. Theravance cited expected annualized savings and indicated the board is exploring strategic options, including a possible sale. Investors pushed the stock down sharply on the readout. For industry watchers, the move underscores how repeated late‑stage failures can force mid‑cap biotechs into survival modes that reshape pipelines and M&A dynamics.